nach oben

Erschienen in:

03.02.2024 | Original Article

Secondary fracture and mortality risk with very high fracture risk osteoporosis and proximal femoral fracture

verfasst von: Hotaka Ishizu, Tomohiro Shimizu, Kosuke Arita, Komei Sato, Renya Takahashi, Kenichi Kusunoki, Shun Shimodan, Tsuyoshi Asano, Norimasa Iwasaki

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

We aimed to investigate secondary fracture and mortality rates, and risk factors in patients with proximal femoral fractures.

Materials and Methods

We conducted a multicenter prospective cohort study on female patients with proximal femoral fractures who underwent surgical treatment between April 2020 and March 2021. Postoperative follow-ups were performed at 6-, 12-, 18-, and 24-month intervals to determine the secondary fracture and mortality rates, and the risk factors and its influence were examined.

Results

Of the 279 registered patients, 144 patients (51.6%) were diagnosed with very high fracture risk osteoporosis. The postoperative osteoporosis rate exceeded 96%; however, osteoanabolic agents were used sparingly. The risk factor of both secondary fracture and mortality was very high fracture risk osteoporosis, and secondary fractures within 12 months were markedly occurred. Secondary fracture rates increased as the number of matched very high fracture risk osteoporosis criteria increased. Notably, secondary fractures and mortality were recorded in 21.4% and 23.5% of the patients who met all criteria, respectively.

Conclusion

Over half of the female patients with proximal femoral fractures had very high fracture risk osteoporosis. Although, very high fracture risk osteoporosis demonstrated a notably increased risk of secondary fractures, particularly at 12 months post-surgery, the use of osteoanabolic agents was substantially low. Collectively, our findings highlight the need to consider the risk of very high fracture risk osteoporosis, expand the use of medications to include osteoanabolic agents, and reconsider the current healthcare approach for proximal femoral fractures.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795. https://doi.org/10.1001/jama.285.6.785

Acevedo C, Stadelmann VA, Pioletti DP, Alliston T, Ritchie RO (2018) Fatigue as the missing link between bone fragility and fracture. Nat Biomed Eng 2:62–71. https://doi.org/10.1038/s41551-017-0183-9CrossRefPubMed

Gopinath V (2023) Osteoporosis. Med Clin North Am 107:213–225. https://doi.org/10.1016/j.mcna.2022.10.013CrossRefPubMed

Migliorini F, Giorgino R, Hildebrand F, Spiezia F, Peretti GM, Alessandri-Bonetti M, Eschweiler J, Maffulli N (2021) Fragility fractures: risk factors and management in the elderly. Medicina (Kaunas). https://doi.org/10.3390/medicina57101119CrossRefPubMed

Sakamoto K, Nakamura T, Hagino H, Endo N, Mori S, Muto Y, Harada A, Nakano T, Itoi E, Yoshimura M, Norimatsu H, Yamamoto H, Ochi T (2006) Effects of unipedal standing balance exercise on the prevention of falls and hip fracture among clinically defined high-risk elderly individuals: a randomized controlled trial. J Orthop Sci 11:467–472. https://doi.org/10.1007/s00776-006-1057-2CrossRefPubMed

Sànchez-Riera L, Wilson N (2017) Fragility fractures & their impact on older people. Best Pract Res Clin Rheumatol 31:169–191. https://doi.org/10.1016/j.berh.2017.10.001CrossRefPubMed

Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, AIoannidis NT, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD (2009) Relation between fractures and mortality: results from the Canadian multicentre osteoporosis study. CMAJ 181:265–271. https://doi.org/10.1503/cmaj.081720CrossRefPubMedPubMedCentral

Okada C (2002) Physical rehabilitation for osteoporotic fractures. Clin Calcium 12:484–488PubMed

Tsuboi M, Hasegawa Y, Suzuki S, Wingstrand H, Thorngren KG (2007) Mortality and mobility after hip fracture in Japan: a ten-year follow-up. J Bone Joint Surg Br 89:461–466. https://doi.org/10.1302/0301-620x.89b4.18552CrossRefPubMed

10.

Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297:387–394. https://doi.org/10.1001/jama.297.4.387CrossRefPubMed

11.

Barton DW, Piple AS, Smith CT, Moskal SA, Carmouche JJ (2021) The clinical impact of fracture liaison services: a systematic review. Geriatr Orthop Surg Rehabil 12:2151459320979978. https://doi.org/10.1177/2151459320979978CrossRefPubMedPubMedCentral

12.

Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone 111:92–100. https://doi.org/10.1016/j.bone.2018.03.018CrossRefPubMed

13.

Chang Y, Huang C, Hwang J, Kuo J, Lin K, Huang H, Bagga S, Kumar A, Chen F, Wu C (2018) Fracture liaison services for osteoporosis in the asia-pacific region: current unmet needs and systematic literature review. Osteoporos Int 29:779–792. https://doi.org/10.1007/s00198-017-4347-yCrossRefPubMed

14.

Hawley S, Javaid MK, Prieto-Alhambra D, Lippett J, Sheard S, Arden NK, Cooper C, Judgegroup REs, A (2016) Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing 45:236–242. https://doi.org/10.1093/ageing/afv204CrossRefPubMedPubMedCentral

15.

Murray AW, McQuillan C, Kennon B, Gallacher SJ (2005) Osteoporosis risk assessment and treatment intervention after hip or shoulder fracture. A comparison of two centres in the united kingdom. Injury 36:1080–1084. https://doi.org/10.1016/j.injury.2005.03.012CrossRefPubMed

16.

Yuan F, Peng W, Yang C, Zheng J (2019) Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis. Int J Surg 66:1–11. https://doi.org/10.1016/j.ijsu.2019.03.004CrossRefPubMed

17.

Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments (in eng). Aging Clin Exp Res 34:695–714. https://doi.org/10.1007/s40520-022-02100-4CrossRefPubMedPubMedCentral

18.

Kostenuik PJ, Binkley N, Anderson PA (2023) Advances in osteoporosis therapy: focus on osteoanabolic agents, secondary fracture prevention, and perioperative bone health. Curr Osteoporos Rep 21:386–400. https://doi.org/10.1007/s11914-023-00793-8CrossRefPubMedPubMedCentral

19.

Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23. https://doi.org/10.1359/jbmr.2003.18.1.18CrossRefPubMed

20.

Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K et al (2011) Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP) (in eng). J Bone Miner Metab 29:37–43. https://doi.org/10.1007/s00774-010-0188-xCrossRefPubMed

21.

Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148. https://doi.org/10.1002/jbmr.5650080915CrossRefPubMed

22.

Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583–1587. https://doi.org/10.1210/jc.2004-0826CrossRefPubMed

23.

Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935. https://doi.org/10.1111/j.1532-5415.1992.tb01992.xCrossRefPubMed

24.

Keith RA, Granger CV, Hamilton BB, Sherwin FS (1987) The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil 1:6–18PubMed

25.

Chang CB, Yang RS, Chang LY, Peng JK, Tsai KS, Huang WJ, Yang TH, Chan DC (2021) One-year outcomes of an osteoporosis liaison services program initiated within a healthcare system. Osteoporos Int 32:2163–2172. https://doi.org/10.1007/s00198-021-05859-wCrossRefPubMed

26.

Frost SA, Kelly A, Gaudin J, Evoy LM, Wilson C, Marov L, El Haddad C, Center J, Eisman JA, Nguyen TV, Hassett G (2020) Establishing baseline absolute risk of subsequent fracture among adults presenting to hospital with a minimal-trauma-fracture. BMC Musculoskelet Disord 21:133. https://doi.org/10.1186/s12891-020-3161-4CrossRefPubMedPubMedCentral

27.

Geusens P, Bours SPG, Wyers CE, van den Bergh JP (2019) Fracture liaison programs. Best Pract Res Clin Rheumatol 33:278–289. https://doi.org/10.1016/j.berh.2019.03.016CrossRefPubMed

28.

Stephens JR, Caraccio D, Mabry DR, Stepanek KV, Jones MS, Hemsey DF, Moore CR (2021) Implementation of a fracture liaison service for patients with hip fracture cared for on a hospital medicine service (in eng). Hosp Pract (1995) 49:41–46. https://doi.org/10.1080/21548331.2020.1832384CrossRefPubMed

29.

Mori T, Tamiya N, Jin X, Jeon B, Yoshie S, Iijima K, Ishizaki T (2018) Estimated expenditures for hip fractures using merged healthcare insurance data for individuals aged ≥ 75 years and long-term care insurance claims data in Japan. Arch Osteoporos 13:37. https://doi.org/10.1007/s11657-018-0448-2CrossRefPubMedPubMedCentral

30.

WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group (in eng). World Health Organ Tech Rep Ser 843:1–129

31.

Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM (1993) Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lancet 341:72–75. https://doi.org/10.1016/0140-6736(93)92555-8CrossRefPubMed

32.

Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P, Vogt TM (1990) Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group (in eng). JAMA 263:665–668CrossRefPubMed

33.

Hui SL, Slemenda CW, Carey MA, Johnston CC Jr (1995) Choosing between predictors of fractures. J Bone Miner Res 10:1816–1822. https://doi.org/10.1002/jbmr.5650101126CrossRefPubMed

34.

Nuti R, Brandi ML, Isaia G, Tarantino U, Silvestri S, Adami S (2009) New perspectives on the definition and the management of severe osteoporosis: the patient with two or more fragility fractures. J Endocrinol Invest 32:783–788. https://doi.org/10.1007/bf03346537CrossRefPubMed

35.

Confavreux CB, Paccou J, David C, Mehsen N, Leboime A, Thomas T (2010) Defining treatment failure in severe osteoporosis. Joint Bone Spine 77:S128–S132. https://doi.org/10.1016/s1297-319x(10)70008-7CrossRefPubMed

36.

Idolazzi L, Maugeri D, Monti S, Massarotti M, Osella G, Barbagallo M, Del Fiacco R, Silvestri S (2016) The Italian observational study on severe osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment. Clin Exp Rheumatol 34:247–253PubMed

37.

Rajzbaum G, Grados F, Evans D, Liu-Leage S, Petto H, Augendre-Ferrante B (2014) Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo observational study. Joint Bone Spine 81:69–75. https://doi.org/10.1016/j.jbspin.2013.05.001CrossRefPubMed

38.

Inose H, Ariga A, Motoyoshi T, Fukushima K, Tomizawa S, Kato T, Takahashi K, Yoshii T, Okawa A (2022) The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: a multicenter retrospective study. JBMR Plus 6:e10637. https://doi.org/10.1002/jbm4.10637CrossRefPubMedPubMedCentral

39.

Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. study of osteoporotic fractures research group. N Engl J Med 332:767–773. https://doi.org/10.1056/nejm199503233321202CrossRefPubMed

40.

Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the Global longitudinal study of osteoporosis in women (in eng). J Bone Miner Res 27:645–653. https://doi.org/10.1002/jbmr.1476CrossRefPubMed

Titel: Secondary fracture and mortality risk with very high fracture risk osteoporosis and proximal femoral fracture
verfasst von: Hotaka Ishizu
Tomohiro Shimizu
Kosuke Arita
Komei Sato
Renya Takahashi
Kenichi Kusunoki
Shun Shimodan
Tsuyoshi Asano
Norimasa Iwasaki
Publikationsdatum: 03.02.2024
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 2/2024
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-023-01492-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Secondary fracture and mortality risk with very high fracture risk osteoporosis and proximal femoral fracture